Big Apple Exclusive: Dr. McCullough Goes Live to Unveil Potential Cancer Breakthrough

The wellness company’s first human observational report suggests that adding the off‑label anti‑infectives ivermectin and mebendazole to standard oncology regimens may produce remission or disease improvement in roughly one‑half of participants after six months. Both agents are inexpensive, generic medications that have been on pharmacy shelves for decades, offering a stark contrast to the rising cost of novel targeted therapies that can exceed hundreds of thousands of dollars per year. The study’s authors highlight a 25 % incidence of mild side effects, yet 94 % of those patients remained on therapy, underscoring a tolerable safety profile.

Despite the promising signal, the investigators stress that the data are observational and lack the rigor of double‑blind, placebo‑controlled trials. They call on the National Cancer Institute and cooperative oncology groups to design dose‑ranging, randomized studies that can confirm efficacy, define optimal dosing schedules, and identify which tumor types respond best. Repurposed drugs historically receive limited research investment, but the oncology field already relies on generic agents for 90 % of cardiovascular therapies, suggesting a feasible pathway for integrating inexpensive, well‑characterized compounds into cancer treatment pipelines.

For clinicians and patients eager to explore these options, the conversation should center on shared decision‑making within a structured trial framework, rather than self‑medication. health/cancer, where the manuscript, dosing guidelines, and enrollment information will be posted once peer review is complete. By embedding ivermectin and mebendazole into formal clinical protocols, the oncology community can systematically track outcomes, manage adverse events, and potentially expand the arsenal of affordable, evidence‑based cancer therapies.